Clinical trial
Intra-Arterial Treatment of Medium-sized Primary Vessel Occlusions: A Randomized Controlled Trial (IMP-ACT)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke NCT06352632
NCT07906275 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 3, 800 participants (estimated). Lead sponsor University of Calgary; Canada. Primary measure: A change of functional dependence analyzed across the whole distribution of outcomes assessed...
How it compares
263 similar trials: same condition (Ischemic Stroke) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intra-Arterial Treatment of Medium-sized Primary Vessel Occlusions: A Randomized Controlled Trial (IMP-ACT)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke NCT06352632
- Lead sponsor
- University of Calgary
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 15, 2026
- Completion date
- March 31, 2031
- Enrollment
- 800 (estimated)
- Sites
- 4
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: medium vessel occlusion, stroke, acute ischemic
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 4
- Countries
- Canada
- Lead sponsor
- University of Calgary
Arms
As registered; 3 arms.
| Arm | Type | Interventions |
|---|---|---|
| Control | Placebo comparator | Intravenous Thrombolysis |
Show registry wordingusual care - intravenous thrombolysis (0.18mg/kg or 0.25mg/kg of tenecteplase) if eligible, plus usual stroke unit care. | ||
| Mechanical EVT | Active comparator | Mechanical Endovascular Thrombectomy |
Show registry wordingTools and technique left to the discretion of the operator; intra-arterial thrombolytic drugs must not be administered. | ||
| Mechanical EVT followed by adjunctive intra-arterial thrombolysis | Active comparator | Mechanical Endovascular Thrombectomy, Tenecteplase/Alteplase- depending upon availability at each treating centre |
Show registry wordingmicrocatheter injection of tenecteplase up to 0.0625 mg/kg (maximum 6.25 mg) or alteplase up to 0.225 mg/kg (maximum 22.5 mg) over 5-10 minutes from a proximal, safe microcatheter position in the affected arterial territory, with agent selected according to local availability. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| A change of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS), | From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner |
Show registry wordingModified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death. | |
Lead sponsor's other trials
University of Calgary, most recent start first.
+697 more trials See the organization page
Similar trials
Same condition (Ischemic Stroke) and phase, most recent start first.
+258 more trials See the condition page